Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Accumulated Expenses (2016 - 2026)

Iradimed has reported Accumulated Expenses over the past 14 years, most recently at $2.1 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 1641.99% to $2.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Mar 2026, up 1641.99% year-over-year, with the annual reading at $144000.0 for FY2025, 22.03% up from the prior year.
  • Accumulated Expenses was $2.1 million for Q1 2026 at Iradimed, up from $144000.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $3.3 million in Q3 2024 and troughed at $94030.0 in Q4 2022.
  • The 5-year median for Accumulated Expenses is $1.6 million (2023), against an average of $1.3 million.
  • Year-over-year, Accumulated Expenses surged 2214.84% in 2023 and then plummeted 95.83% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $94030.0 in 2022, then increased by 24.92% to $117463.0 in 2023, then increased by 0.46% to $118000.0 in 2024, then grew by 22.03% to $144000.0 in 2025, then soared by 1334.72% to $2.1 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Accumulated Expenses are $2.1 million (Q1 2026), $144000.0 (Q4 2025), and $137025.0 (Q3 2025).